New Pharmacogenomics Course Offered
A new continuing education course in pharmacogenomics is now available to prescribers interested in personalized medicine. This course was made possible through a partnership between Genelex and Ohio Northern University’s Raabe College of Pharmacy.
The course, called Application of Pharmacogenetics, is hosted and licensed through Ohio Northern University (ONU) facilitated by our own Brian Hocum, PharmD. The course covers the fundamental aspects, methods, and benefits of pharmacogenetics, including: identifying important drug interaction mechanisms, describing the clinical impact, understanding pharmacogenetic information, how to recognize which patients will benefit most, and how to work with patient drug regimens.The course counts as one continuing education credit.
Emphasis on Personalized Medicine
Ohio Northern University is special due to their Raabe College of Pharmacy’s emphasis on personalized medicine. As Dr. Jon E. Sprague, Dean of Raabe College, says on their website, “We are the only school of pharmacy to put an emphasis on pharmacogenetic testing.”
Dr. Hocum has been working with Dr. Andrew Roecker, Chair, to implement this new course. Genelex has had a previous relationship with ONU, but this is the first time we’ve partnered with a university to offer continuing education. The program will be available through November 30th, 2015.
More Options for Continuing Education
In addition to Ohio Northern University’s course, Genelex also recommends prescribers consider continuing education through the American College of Clinical Pharmacology and Drugstore News. Genelex is also currently pursuing other possible venues for further continuing education, including offering in-office visits with our personalized prescribing professionals. Interested parties can click here to view CE options.
Take a Risk Assessment
Simply enter the medications you’re currently on or plan to take. Click “Get Results” to see if your regimen puts you at risk for an adverse drug reaction.
YOUR GENELEX RISK ASSESSMENT RESULTS: